Ann: Positive results received for Emyrias MDMA-inspired program, page-35

I appreciate your comment, like you said, near impossible estimating potential company “value”, in general, values seem to swing between over and undervalued. My opinion is of the conservative nature, I don’t enjoy the sprouting of “not long now until $2”, give it a rest. Yes we’re ticking boxes and while we do that we’ll hopefully crawl vertically.

I stopped following IHL so the knowledge about the Dr jumping ship is very interesting, thanks for the that.

At the end of the day we’re all invested, some from and for a personal perspective and others to make coin. So increasing both value of the company and clinical studies is beneficial for everyone. Let’s enjoy the ride and keep it realistic!

cheers mate.